Is the Phase 3 Trial Data for MDMA Therapy sets Path for FDA Approval?

by EmpathiCSubstanceS | Jan 14, 2022 | Neuropathy, NN-Dimethyltryptamine, OCD, San Pedro Mescaline

The first results from Phase 3 trials testing MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) have been announced. The extremely promising data are the first Phase 3 results to be revealed for any psychedelic-based therapy, paving the way for a...

Taking Psychedelics doesn’t Make You a Better or More Peaceful Person.

by EmpathiCSubstanceS | Jan 14, 2022 | LSD, MDMA Sassafras Molly, Microdosing, Neuropathy, NN-Dimethyltryptamine, OCD, Pain, Parkinson's Disease

Another myth being commercialized is that psychedelic drugs will make you a peaceful, righteous human. The notion that the world’s problems would be solved if more people took entheogens is a hallucination in and of itself. However, there are countless examples of...

What Does Psychedelic Therapy Against Traditional Antidepressant Trial Pits Looks Like?

by EmpathiCSubstanceS | Jan 14, 2022 | Cancer, Cannabis Marijuana, Chronic Pain, Depression, LSD, Neuropathy, Pain, Psychotropics

A first-of-its-kind clinical trial has pitted a common antidepressant against psilocybin, the main psychedelic compound found in magic mushrooms. The results, recently published in the New England Journal of Medicine, are decidedly mixed with the primary depression...

Is Depression a Brain Disorder or Dysfunction, Are There Potential Therapeutic Targets?

by EmpathiCSubstanceS | Jan 13, 2022 | CBC, Cluster Headaches, DMT, Iboga, Kambo, LSD, MDMA Sassafras Molly, Neuropathy, OCD, Parkinson's Disease

Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or...

Why Psychedelic Therapy Research Gets First US Government Funding in Decades?

by EmpathiCSubstanceS | Jan 13, 2022 | Iboga, MDMA Sassafras Molly, Neuropathy, OCD, Parkinson's Disease, Psilocybin Magic Mushroom, San Pedro Mescaline

The latest research into psilocybin therapy as a treatment for tobacco addiction has yielded promising results. Johns Hopkins Medicine was awarded a US$4-million grant by the National Institutes of Health (NIH) to further clinical research investigating...

Is Microdosing Considered a Sport Performance-Enhancing?

by EmpathiCSubstanceS | Jan 13, 2022 | Iboga, LSD, MDMA Sassafras Molly, Microdosing, Neuropathy, NN-Dimethyltryptamine, OCD, Psilocybin Magic Mushroom

With scientists now beginning to investigate the popular phenomenon of microdosing there are only anecdotes and reports from citizen scientists offering insights into the possible performance-enhancing effect of this behavior. The few published studies on microdosing...